Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR) — Stella

Home/Diabetic Retinopathy/Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

View on ClinicalTrials.gov

Recruiting

Back to Diabetic Retinopathy trials

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

Trial locations(1 site)

United States

University of Alabama at Birmingham, Birmingham, Alabama

Key details

Sponsor

University of Alabama at Birmingham

Enrollment target

~104 participants

Started

January 2018

Primary completion

December 2026

Age range

21 Years – 98 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.